These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 29750399

  • 1. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [Abstract] [Full Text] [Related]

  • 2. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB.
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Single-agent Bevacizumab in the Treatment of Symptomatic Newly Diagnosed and Recurrent/Refractory Pediatric Cervicomedullary Brainstem Low-grade Gliomas: A Single Institutional Experience.
    Sridhar S, Paul MR, Yeh-Nayre L, Khanna PC, Elster J, Aristizabal P, Crawford JR.
    J Pediatr Hematol Oncol; 2023 Jan 01; 45(1):e21-e25. PubMed ID: 35426868
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H, Ohno M, Igaki H, Miyakita Y, Takahashi M, Tamura Y, Shima S, Matsushita Y, Ichimura K, Narita Y.
    Jpn J Clin Oncol; 2021 Jul 01; 51(7):1028-1035. PubMed ID: 33959771
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab in treating the cystic components of pediatric low-grade gliomas: A report of four patients.
    Levenbaum E, Ellika S, Korones DN.
    Pediatr Blood Cancer; 2019 Nov 01; 66(11):e27917. PubMed ID: 31347764
    [Abstract] [Full Text] [Related]

  • 7. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
    Hsu CH, Lober RM, Li MD, Partap S, Murphy PA, Barnes PD, Fisher PG, Yeom KW.
    J Neurooncol; 2015 May 01; 122(3):491-6. PubMed ID: 25758812
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.
    Neuro Oncol; 2010 Sep 01; 12(9):985-90. PubMed ID: 20363768
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS.
    Cancer Res Treat; 2017 Jan 01; 49(1):129-140. PubMed ID: 27188199
    [Abstract] [Full Text] [Related]

  • 13. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
    Pace A, Mandoj C, Antenucci A, Villani V, Sperduti I, Casini B, Carosi M, Fabi A, Vidiri A, Koudriavtseva T, Conti L.
    J Neurooncol; 2018 Jul 01; 138(3):527-535. PubMed ID: 29594657
    [Abstract] [Full Text] [Related]

  • 14. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC, Johnston SK.
    J Neurooncol; 2010 Jan 01; 96(2):259-69. PubMed ID: 19593660
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
    Chamberlain MC, Johnston S.
    J Neurooncol; 2009 Feb 01; 91(3):359-67. PubMed ID: 18953491
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.